Heart Rate Response after Heart Transplantation

Sissel Nygaard, MD¹; Katrine Rolid, PT²; Kari Nytrøen, PT, PhD²; Arnt Fiane,MD, PhD, Prof³; Vegard Bruun Bratholm Wyller, MD, PhD, Prof⁴Lars Gullestad, MD, PhD, Prof²; Kaspar Broch, MD, PhD²

¹Department of Pediatric Cardiology, Oslo University Hospital, Norway; ²Department of Cardiology and ³Department of Cardiothoracic Surgery, Oslo University Hospital, Norway; ⁴Department of Pediatric Cardiology, Akershus University Hospital, Lørenskog, Norway

INTRODUCTION

Denervation at heart transplant (HTx) results in attenuated heart rate (HR) control and limited exercise tolerance.

PURPOSE

The aim of this study was to assess longitudinal changes in the HR response to exercise in HTx recpients. We compared the results with those of healthy controls.



METHODS

The HR response to maximal cardiopulmonary exercise was tested in 50 *de* novo HTx recipients at 11 weeks (range 7-16) after surgery, at 1-year follow-up and in 50 age and gender matched controls. The HR was measured at rest, at 25-, 50-, 75-, and 100% of $\mathrm{VO}_{\mathrm{2peak}},$ and 30 sec, 1, 2, 3 and 4 min after peak exercise on a treadmill or bicycle ergometer. We also assessed the HR reserve and the chronotropic response index.


RESULTS

11 weeks after HTx, the HR response to exercise was blunted, but improved significantly during follow-up. The change in HR from rest to peak exercise increased by 48% (46 bpm vs 68 bpm; p<0.001) from inclusion to the 12 months' follow-up (Figure). In comparison, the change in HR during exercise in controls was 115 bpm. In HTx recipients, approximately 50% of the total increase in HR occurred between rest and 25% of VO_{2peak} (figure). In the controls, roughly 40% of the total increase in HR occurred during the initial 25% of VO_{2peak}. The HTx recipients had a significantly higher change in HR between 75- and 100% of VO_{2peak} at inclusion than at 1-year follow-up (p=0.004) and this delayed change in HR was higher than in controls (p = 0.001). The chronotropic response index increased during follow-up (0.48 \pm 0.2 vs 0.79 \pm 0.2; p< 0.001) and normalized in 50% of the HTx recipients at 1 year. Finally, the HR declined more rapidly after exercise at follow-up than at inclusion, however, the decline remained slower than in controls (Figure).

Table 1. Cardiopulmonary Exercise Test					Change in heart rate related to VO2 during exercise in hear transplant recpients and healthy controls
	Baseline	12 months	p-value for change	Healthy controls	p<0.001 for all comparisons between
IR rest (beats/min)	85 (10,8	86 (10,2)	0.39	61 (8,3)	Heart Transplant Recipients and Healthy
IR 25% VO2 (beats/min)	105 (12,2)	117 (12,1)	< 0.001	107 (15,0)	Controls at each stage
R 50% VO2 (beats/min)	111 (13,9)	127 (15,8)	<0.001	132 (15,1)	De La
R 75% VO2 (beats/min)	117 (16,3)	139 (18,9)	< 0.001	157 (16,3(IR)	0 0
R max (beats/min)	128 (18,9)	151 (20,7)	<0.001	178 (16,1(IR)	pead and a set of the
IR max, % of predicted	73,1 (12,4)	88,6 (12,6)	<0.001	103,4 (6,5(IR)	a state o
IR reserve (beats/min)	41 (17,9)	65 (19,3)	<0.001	122 (17,3)	T I I
RI	0,48 (0,21)	0,79 (0,24)	<0.001	1,05 (0,01)	
ER	1,19 (0,1)	1,2 (0,1)	0.71	1,26 (0,09)	
O2 peak (mL/kg/min)	21,1(5,0)	24,7 (6,7)	<0.001	40,3 (7,9)	
O2 peak , % of predicted	56,5 (13,0)	67,2 (16,3)	<0.001	107,3 (16,2)	Change *
BP rest (mm Hg)	121 (12,9)	118 (16,3)	0.01	109 (13,6)	
PB rest (mm Hg)	79 (30,2)	79 (16,3)	<0.001	72 (72 (10,3)	
PB max (mm Hg)	187 (30,2)	212 (32,1)	0.02	204 (26,2)	ΔHR 25% VO2 (%) ΔHR 50% VO2 (%) ΔHR 75% VO2 (%) ΔHR 100% V
DPB max (mm Hg)	83 (17,1)	86 (18,1)	0.90	85 (18,1)	Baseline 12 mo Healthy CT

index; RER, respiratory exchange ratio







REFERENCES 1.

- Nytroen, K; Myers, J; Chan, K.N Chronotropic responses to exercise in heart transplant recipients: 1-year follow-up. Am J Phys Med Rehab 2011 Jul;90(7):579-88. doi: 10.1097/PHM.0b013e31821f711d Awad, M: Czer, L: Hou, M
- Early Denervation and Later Reinnervation of the Heart Following Heart Transplantation: A Review. J Am Heart Assoc 2016, 5(11): e004070

Disclosure Statement: The authors have no relevant financial relationships related to this presentation and there are no discussions of off label or investigational use of drug or devices

